Artelo Biosciences Reports Promising Data on ART12.11 Solid Dosage Form at CT-CANN24

Artelo Biosciences, Inc., a pharmaceutical company specializing in lipid-signaling pathway modulation, recently presented promising pre-clinical data on ART12.11. This data, unveiled at the CT-CANN24 conference in London, suggests that ART12.11, a patented co-crystal of cannabidiol (CBD) and tetramethylpyrazine (TMP), exhibits pharmacokinetics comparable to Epidiolex®. 

Dr. Andrew Yates, Artelo’s Chief Scientific Officer, revealed that ART12.11, even in an unoptimized form, demonstrated similar pharmacokinetic profiles of CBD and its metabolites when compared to Epidiolex. Epidiolex is an FDA-approved oral CBD solution used primarily to control seizures in rare childhood disorders, which reported net sales exceeding $845 million in 2023.

The company believes that moving from an oral solution to a solid dosage form such as tablets could offer benefits like precise dosing and easier storage. Dr. Yates expressed excitement about ART12.11’s potential: “The data shows we can match an Epidiolex-like formulation and that ART12.11 can achieve similar CBD levels in plasma. This gives us confidence in developing an optimized solid-dosage form for broader clinical research.”

ART12.11’s development has already shown promising results. In a previous animal study, ART12.11 outperformed pure CBD in reducing stress-induced anxiety and depression, using only a third of the CBD amount required by the comparator arm. This indicates a potential reduction in the number of pills patients might need, making treatment more manageable.

Artelo Biosciences is now focusing on advancing ART12.11 into clinical studies, aiming to harness its superior pharmaceutical properties. ART12.11 has shown improved pharmacokinetics, including better absorption and bioavailability, compared to traditional CBD forms. The company holds a composition of matter patent for ART12.11 in the United States, effective until December 2038.

Artelo Biosciences, Inc. remains committed to developing treatments for conditions like cancer, pain, and neurological disorders by targeting lipid-signaling pathways. Their team, consisting of experienced biopharmaceutical executives and respected researchers, strives to bring high-impact therapies to market.

CT-CANN24 serves as a platform for leading experts to discuss advancements in cannabinoid research and clinical applications. The conference is a gathering point for professionals worldwide to share new data and explore future research possibilities in this rapidly evolving field.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!